Here's some interesting news from ddn (Drug Discovery News):
SEOUL, South Korea—Aimed at enhancing the clinical outcomes of patients suffering from liver cancer, Samsung Medical Center and Pfizer Inc. have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles that could hold the keys to more effective therapies.
Under the terms of the partnership, Seoul-based Samsung will provide the patient samples, while Pfizer will conduct genomic profiling on the samples and analyze the data in order to link gene signatures to patient outcomes.
Read more here.
No comments:
Post a Comment